Expression Pathology, the leading provider of FFPE tissue-based proteomics, and Flagship Biosciences, the leading digital pathology services firm, announce a service partnership that enables tissue translational biomarker development, validation and application in support of drug development.
Many pharmaceutical, biotech and academic clinical research organizations require robust targeted assays to translate and validate their biomarker discovery efforts with respect to protein expression in tissue. Customers of Expression Pathology and Flagship can now leverage expertise with tissue biomarkers to quickly develop quantitative evidence-based assays using the combined know how of mass-spec tissue analysis and digital pathology. Flagship’s pathology expertise to ensure the right tissue or sub anatomic organelle is analyzed combined with Expression Pathology’s expertise in multiplex tissue proteomic assays using FFPE tissue offers comprehensive tissue analysis service to customers.
“Expression Pathology’s unique and proprietary Liquid Tissue® SRM assays for quantitative analyses of proteins in FFPE tissue are opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions” said Casey Eitner, President and CEO of Expression Pathology Inc.
“Translational and personalized medicine today requires better integration of the enabling technologies these platforms and new generation of service organizations provide,” said John Bloom, a member of Flagship’s Board of Directors and a well-known leader in translational medicine. “This novel partnership is prototypic of what is required to meet the needs of drug development and patient care in this dynamic area of applied biomarker science.”
Expression Pathology Inc. (EPI) is a private biotechnology company leading the development of innovative assays to measure functional tissue proteins in research and diagnostic applications.
Flagship Biosciences LLC is a pathologist-owned contract research organization that delivers quantitative pathology and tissue-based companion diagnostics in drug and device development.